RightEye, an eye-tracking biomarker company, has signed a research collaboration agreement with the Massachusetts Institute of Technology (MIT) to study a potential eye-motion “signature” for diagnosing Lyme disease.
MIT’s lead investigator on the project, known for her work in Borrelia burgdorferi imaging, is Michal Caspi Tal, PhD, an instructor and team lead at the Institute for Stem Cell Biology and Regenerative Medicine at Stanford University, and a visiting scientist at MIT’s Department of Bioengineering.
“Over 10 percent of people who have Lyme disease go on to suffer from chronic disease. It is unclear why some return to health while others do not,” said Tal. “We hope this research may provide answers for those who develop chronic symptoms after Lyme disease. This could lead to interventions that may reduce or even mitigate chronic symptoms after Lyme disease.”
RightEye has been researching evidence linking eye behavior to brain damage for more than 30 years. They are currently developing vision diagnostic systems for concussions, Parkinson’s disease, and other movement disorders.
Their Chief Science Officer and co-founder Melissa Hunfalvay, PhD, added, “The widely accepted shortcomings of the [Lyme disease] ELISA and Western Blot Tests significantly increase the importance of this study. Hunfalvay says the team has recently begun the data collection process.
Read more
|